INSMED INC (INSM) Stock Fundamental Analysis
USA - NASDAQ:INSM - US4576693075 - Common Stock
192.31 USD
-2.08 (-1.07%)
Overall INSM gets a fundamental rating of 4 out of 10. We evaluated INSM against 531 industry peers in the Biotechnology industry. The financial health of INSM is average, but there are quite some concerns on its profitability. INSM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
INSM had negative earnings in the past year.
In the past year INSM has reported a negative cash flow from operations.
INSM had negative earnings in each of the past 5 years.
In the past 5 years INSM always reported negative operating cash flow.
1.2 Ratios
INSM's Return On Assets of -50.15% is in line compared to the rest of the industry. INSM outperforms 49.72% of its industry peers.
With a Return On Equity value of -125.20%, INSM perfoms like the industry average, outperforming 40.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.15% | ||
| ROE | -125.2% | ||
| ROIC | N/A |
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of INSM (76.54%) is better than 84.18% of its industry peers.
INSM's Gross Margin has been stable in the last couple of years.
INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
2. Health
2.1 Basic Checks
INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INSM has been increased compared to 1 year ago.
Compared to 5 years ago, INSM has more shares outstanding
The debt/assets ratio for INSM has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 13.85 indicates that INSM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.85, INSM belongs to the top of the industry, outperforming 86.44% of the companies in the same industry.
A Debt/Equity ratio of 0.59 indicates that INSM is somewhat dependend on debt financing.
INSM's Debt to Equity ratio of 0.59 is on the low side compared to the rest of the industry. INSM is outperformed by 73.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.85 |
ROIC/WACCN/A
WACC8.61%
2.3 Liquidity
A Current Ratio of 4.63 indicates that INSM has no problem at all paying its short term obligations.
The Current ratio of INSM (4.63) is comparable to the rest of the industry.
INSM has a Quick Ratio of 4.34. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
INSM has a Quick ratio (4.34) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.34 |
3. Growth
3.1 Past
INSM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.53%.
The Revenue has grown by 30.34% in the past year. This is a very strong growth!
Measured over the past years, INSM shows a very strong growth in Revenue. The Revenue has been growing by 21.65% on average per year.
EPS 1Y (TTM)-11.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.8%
Revenue 1Y (TTM)30.34%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%52.36%
3.2 Future
INSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.04% yearly.
The Revenue is expected to grow by 70.63% on average over the next years. This is a very strong growth
EPS Next Y-8.3%
EPS Next 2Y16.15%
EPS Next 3Y20.68%
EPS Next 5Y29.04%
Revenue Next Year37.89%
Revenue Next 2Y77.94%
Revenue Next 3Y79.53%
Revenue Next 5Y70.63%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
INSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INSM's earnings are expected to grow with 20.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.15%
EPS Next 3Y20.68%
5. Dividend
5.1 Amount
No dividends for INSM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INSM (11/13/2025, 3:21:51 PM)
192.31
-2.08 (-1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.73%
Inst Owner Change3.77%
Ins Owners0.67%
Ins Owner Change-11.14%
Market Cap40.65B
Revenue(TTM)447.02M
Net Income(TTM)-1.18B
Analysts85.38
Price Target178.15 (-7.36%)
Short Float %4.54%
Short Ratio4.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.48%
Min EPS beat(2)-28.87%
Max EPS beat(2)-28.09%
EPS beat(4)0
Avg EPS beat(4)-18.15%
Min EPS beat(4)-28.87%
Max EPS beat(4)-4.46%
EPS beat(8)1
Avg EPS beat(8)-14.89%
EPS beat(12)2
Avg EPS beat(12)-15.58%
EPS beat(16)4
Avg EPS beat(16)-11.73%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)1.43%
Max Revenue beat(2)20.71%
Revenue beat(4)2
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-1.17%
Max Revenue beat(4)20.71%
Revenue beat(8)3
Avg Revenue beat(8)1.76%
Revenue beat(12)4
Avg Revenue beat(12)1.09%
Revenue beat(16)6
Avg Revenue beat(16)1.62%
PT rev (1m)13.59%
PT rev (3m)51.11%
EPS NQ rev (1m)-10.46%
EPS NQ rev (3m)-6.3%
EPS NY rev (1m)-7.71%
EPS NY rev (3m)-12.09%
Revenue NQ rev (1m)10.18%
Revenue NQ rev (3m)11.89%
Revenue NY rev (1m)5.77%
Revenue NY rev (3m)9.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 90.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 42.99 | ||
| P/tB | 56.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.19
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-4.29
FCFYN/A
OCF(TTM)-4.18
OCFYN/A
SpS2.11
BVpS4.47
TBVpS3.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.15% | ||
| ROE | -125.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.54% | ||
| FCFM | N/A |
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score3
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 139.18% | ||
| Cap/Sales | 5.09% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.34 | ||
| Altman-Z | 13.85 |
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.8%
EPS Next Y-8.3%
EPS Next 2Y16.15%
EPS Next 3Y20.68%
EPS Next 5Y29.04%
Revenue 1Y (TTM)30.34%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%52.36%
Revenue Next Year37.89%
Revenue Next 2Y77.94%
Revenue Next 3Y79.53%
Revenue Next 5Y70.63%
EBIT growth 1Y-40.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.85%
EBIT Next 3Y24.22%
EBIT Next 5YN/A
FCF growth 1Y-72.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.7%
OCF growth 3YN/A
OCF growth 5YN/A
INSMED INC / INSM FAQ
What is the fundamental rating for INSM stock?
ChartMill assigns a fundamental rating of 4 / 10 to INSM.
What is the valuation status of INSMED INC (INSM) stock?
ChartMill assigns a valuation rating of 1 / 10 to INSMED INC (INSM). This can be considered as Overvalued.
How profitable is INSMED INC (INSM) stock?
INSMED INC (INSM) has a profitability rating of 2 / 10.
What is the earnings growth outlook for INSMED INC?
The Earnings per Share (EPS) of INSMED INC (INSM) is expected to decline by -8.3% in the next year.